APA
Rajajeyabalachandran G., Kumar S., Murugesan T., Ekambaram S., Padmavathy R., Jegatheesan S. K., Mullangi R. & Rajagopal S. (20170605). Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. : Expert opinion on therapeutic targets.
Chicago
Rajajeyabalachandran Gurukumari, Kumar Swetha, Murugesan Thanabal, Ekambaram Shanthi, Padmavathy Ramya, Jegatheesan Sooriya Kumar, Mullangi Ramesh and Rajagopal Sriram. 20170605. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. : Expert opinion on therapeutic targets.
Harvard
Rajajeyabalachandran G., Kumar S., Murugesan T., Ekambaram S., Padmavathy R., Jegatheesan S. K., Mullangi R. and Rajagopal S. (20170605). Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. : Expert opinion on therapeutic targets.
MLA
Rajajeyabalachandran Gurukumari, Kumar Swetha, Murugesan Thanabal, Ekambaram Shanthi, Padmavathy Ramya, Jegatheesan Sooriya Kumar, Mullangi Ramesh and Rajagopal Sriram. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. : Expert opinion on therapeutic targets. 20170605.